Summary
Ceftazidime was used as monotherapy for 30 febrile episodes in 28 patients, who underwent allogeneic bone marrow transplantation and who were treated concomitantly with the immunosuppressive agent cyclosporin-A. Ceftazidime did not enhance the well established nephrotoxicity of cyclosporin-A as measured by serum creatinine levels or creatinine clearnace. Although an increasing number of Gram-positive infections in these patients warrants vigilance, ceftazidime as initial empirical monotherapy proved to be successful in 95% of all febrile post-transplantation patients. All Gram-negative and 69% of the Grampositive infections were cured with ceftazidime alone. The overall clinical cure rate was 72%, with microbiological clearance in 63%. This compares favourably with aminoglycoside containing schedules and avoids the aminoglycoside associated nephrotoxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atkinson K, Storb R, Prentice RL, Weiden PL, Witherspoon RP, Sullivan K, Noel D, Thomas ED (1971) Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 53: 720–731
Bennet WM, Pulliam JP (1983) Cyclosporin nephrotoxicity. Ann Intern Med 99: 851–854
Bodey GP (1984) Antibiotics in patients with neutropenia. Arch Intern Med 144: 1845–1851
Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB (1984) Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann Intern Med 101: 667–682
Donnelly JP, Marcus RE, Goldman JM, Cohen J, Worsely AM, Catovsky D, Darrell JH, Want SV, Galton DAG (1985) Ceftazidime as first line therapy for fever in acute leukaemia. J Infect 11: 205–215
Hows JM, Kaffaf S, Palmer S, Harris R, Fairhead S, Gordon-Smith EC (1982) Regeneration of peripheral blood cells following allogeneic bone marrow transplantation for severe aplastic anaemia. Br J Haematol 52: 551–558
Hows JM, Chipping PM, Fairhead S, Smith J, Baughan A, Gordon-Smith EC (1983) Nephrotoxicity in bone marrow transplant recipients treated with cyclosporin A. Br J Haematol 54: 69–78
Kahan BD (1983) Meeting report: The first international congress on cyclosporin: Houston, Texas: May 16–19; Dial Transplantation 12: 6320–6339
Kahan BD, Bennett WM (1985) Cyclosporin-associated renal injury. Transplant Proc XVII (Suppl 1) 4: 196–201
Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED (1983) Acute renal toxicity with combined use of amphotericine B and cyclosporin after marrow transplantation. Transplantation 35: 211–215
Lum LG, Seigneuret MC, Storb R, Witherspoon RP, Thomas ED (1981) In vitro regulation of immunoglobulin synthesis after marrow transplantation I. T cell and B cell deficiencies in patients with and without chronic graft-versus-host disease. Blood 58: 431–439
Neu HC (1982) The new beta-lactamase-stable cephalosporins. Ann Intern Med 97: 408–419
de Pauw BE, Kauw F, Muytjens H, Williams K, Bothof Th (1983) Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother (Suppl A) 12: 93–99
de Pauw B, Williams K, de Neeff T, Bothof T, de Witte T, Holdrinet R, and Haanen C (1985) A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Chemother 28: 824–828
de Pauw BE, Bothof J, Williams K, Holdrinet R, de Witte T (1985) A randomized study of ceftazidime alone versus ceftazidime plus cephalothin in febrile neutropenic patients. 14th ICC Kyoto, June. Session P 52 (Abstract 54)
Pizzo PA, Ladisch S, Simon RM, Gill F, Levine AS (1978) Increasing incidence of Gram-positive sepsis in cancer patients. Med Pediatr Oncol 5: 241–244
Powles RL, Clinc HM, Spence D, Morgenstern G, Watson JG, Selby PJ, Woods M, Barrett A, Jameson B, Sloane J, Lawler SD, Kay HEM, Lawson D, McElwain TJ, Alexander P (1980) Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation. Lancet 1: 327–329
O'Reilly RJ (1983) Allogeneic bone marrow transplantation: current status and future directions. Blood 62: 941–964
Ringden O, Myrenfors P, Klintmalm G, Tyden G, Ost L (1984) Nephrotoxicity by cotrimoxazole and cyclosporin in transplanted patients. Lancet 1: 1016–1017
Shulman H, Striker J, Deeg HJ, Kennedy MS, Storb R, Thomas ED (1981) Nephrotoxicity of cyclosporin-A after allogeneic marrow transplantation. N Engl J Med 305: 1392–1395
Wade JC, Schimpff SC, Newman KA, Wiernik PH (1982) Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 97: 503–508
Whiting PH, Simpson IG, Thomson AW (1983) Nephrotoxicity of cyclosporin in combination with aminoglycoside and cephalosporin antibiotics. Transplant Proc 15: 2702–2706
Witherspoon RP, Storb R, Ochs HD, Flournoy N, Kopecky KJ, Sullivan KM, Deeg HJ, Sosa R, Noel DR, Atkinson K, Thomas (1981) Recovery of antibody production in human allogeneic marrow graft recipients: influence of time post-transplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 58: 360–368
De Witte T, Raymakers R, Plas A, Koekman E, Wessels H, Haanen C (1984) Bone marrow repopulation capacity after allogeneic bone marrow transplantation of lymphocytes depleted bone marrow using counterflow centrifugation. Transplantation 37: 151–155
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Verhagen, C., de Pauw, B.E., de Witte, T. et al. Ceftazidime does not enhance cyclosporin-a nephrotoxicity in febrile bone marrow transplantation patients. Blut 53, 333–339 (1986). https://doi.org/10.1007/BF00320893
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320893